Tag - Akston Biosciences

Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-Stable COVID-19 Vaccine at Global Scale

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, today announced a commercial agreement with Seppic S.A., a supplier of specialty healthcare ingredients, for the supply of adjuvant for use in Akston’s COVID-19 Fc fusion protein vaccine candidate, AKS-452. Read more >>

Amid surging Covid-19 cases, second gen vaccines raise hopes across the Asia-Pacific

The United Nations High Commissioner for Refugees sounded the alarm at the beginning of this month on the rapidly deteriorating circumstances of refugees and asylum seekers in Asia…

After the first spate of vaccine approvals at the beginning of this year, a slew of new vaccines will not only bolster global supply, thereby improving access, but also offer an improvement on extant vaccines…

One such second-generation vaccine, produced by US-based Akston Biosciences, is especially well-suited for hot regions such as ASEAN […]

The Right Shots In The Right Places

Row Covid-19 or Coronavirus vaccine flasks on white background

Every safe and effective Covid-19 vaccine is helping to end the global pandemic. But that doesn’t mean they’re all the same. To succeed globally, though, we can’t just focus on what works best on our own shores. A temperature-sensitive vaccine shipped to a facility without freezers will go to waste. Scheduling two doses isn’t feasible for every population. In developing countries, these challenges can be acute. More remarkably, Akston Biosciences has […]

Second gen vaccines could hold key to vanquishing virus

The week-long lockdown comes at a time when India is in the midst of a veritable health crisis; not only are many of its ICUs being overwhelmed by an exponential surge in cases of the virus, but the problem is also being compounded by significant vaccine shortages…

Fortunately, there are over 270 novel candidates in development as part of a so-called second generation of vaccines, which could solve the logistical problems posed by the already approved alternatives.

In the Netherlands, for example, Akston […]

AKS-452: The newest vaccine – COVID-19 shot developed by Beverly company reaches trial stage

A COVID-19 vaccine developed by a company in Beverly is being tested on volunteers in the Netherlands. Akston Biosciences announced this week that the first participants in a clinical trial have received doses of its vaccine, called AKS-452. The company is hoping to get approval from European regulators and then seek approval in the United States. Read more >>

Small, local biotechs make progress on their own Covid-19 drugs

The biggest players in the Covid-19 space are the ones that dominate the headlines: Moderna Inc. with its promising new vaccine booster shot candidates, Pfizer and BioNTech with boosters of their own in development and Gilead Sciences, Eli Lilly and Regeneron with antivirals and antibody treatments. But as the pandemic continues around the globe, small Massachusetts firms are developing potential vaccines and treatments of their own — and two of them hit milestones in that process this week. Read […]

Africa’s need for a dedicated Covid-19 vaccine supply

As with so many other facets of global wealth (and health) inequality, the rollout of the four Covid-19 vaccines produced by Western pharmaceutical companies and approved by American and European health officials – the “Big Four” of Pfizer/BioNTech, Moderna, Oxford/AstraZeneca, and Johnson & Johnson – has quickly became yet another tale of haves and have-nots…

Fortunately, a new slate of vaccines fit for use in the least-developed areas of sub-Saharan Africa are currently undergoing trials and could soon offer African […]

Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in an open-label trial of AKS-452, its COVID-19 vaccine candidate. The trial is managed by TRACER Europe B.V., a CRO specializing in fast-track clinical trials; and is being conducted at the University Medical Center Groningen (UMCG), one of the largest hospitals in the Netherlands. It will test both one- and two-dose regimens, each at three-dose levels. Read more >>